.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XD07_Padeliporfin.Padeliporfin

Information

Padeliporfin (also known as Tookad) is a photosensitizing agent used in photodynamic therapy, most notably for the treatment of low-risk prostate cancer. It is approved in some countries, notably in Europe, for this use and acts by generating cytotoxic reactive oxygen species when activated by near-infrared light, leading to vascular shutdown and tumor ablation.

Pharmacokinetics

Pharmacokinetic parameters are based on adult male patients with localized prostate cancer receiving intravenous infusion of padeliporfin during clinical trials.

References

1. Fabre, MA, et al., & Ficheux, H (2007). Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling. Journal of pharmaceutical sciences 96(12) 3444–3456. DOI:10.1002/jps.21018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17854075

Revisions

• 06/2025 initial generated model